Patents by Inventor Christina Esdar
Christina Esdar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11939314Abstract: Compounds of the formula I in which X1, X2, X3, X4, R1, R2, R3, Q and Y have the meanings indicated in claim 1, are inhibitors of c-Kit kinase, and can be employed for the treatment of cancer.Type: GrantFiled: October 12, 2021Date of Patent: March 26, 2024Assignee: MERCK PATENT GMBHInventors: Dieter Dorsch, Mathilde Muzerelle, Lars Burgdorf, Margarita Wucherer-Plietker, Paul Czodrowski, Christina Esdar, Christos Tsaklakidis
-
Patent number: 11858951Abstract: ?-Amino boronic acid derivatives are useful for inhibiting the activity of immunoproteasome (LMP7) and for the treatment and/or prevention of medical conditions affected by immunoproteasome activity such as inflammatory and autoimmune diseases, neurodegenerative diseases, proliferative diseases, and cancer.Type: GrantFiled: January 31, 2022Date of Patent: January 2, 2024Assignee: Merck Patent GmbHInventors: Markus Klein, Oliver Schadt, Christina Esdar
-
Publication number: 20230346815Abstract: Alpha-amino boronic acid derivatives are useful for selectively inhibiting the activity of immunoproteasome subunit LMP7 and for the treatment of medical conditions affected by immunoproteasome activity such as blood disorders and solid tumors, which are defined by specific genetic alterations and/or inadequate responsiveness to other therapeutic treatments. In particular, the compounds disclosed herein are selective LMP7 inhibitors, which may be useful alone or in combination for the treatment of blood disorders, such as multiple myeloma, and certain solid tumors.Type: ApplicationFiled: October 5, 2021Publication date: November 2, 2023Applicant: Merck Patent GmbHInventors: Christina ESDAR, Manja FRIESE-HAMIM, Michael SANDERSON, Gina WALTER-BAUSCH
-
Patent number: 11597771Abstract: The present invention relates to antibodies with specificity for FGFR1. More particularly, the invention relates to monoclonal antibodies that bind specifically to and neutralize human, macaque and mouse forms of FGFR1 with high affinity. The invention also relates to nucleic acids encoding said antibodies, vectors for expression of these nucleic acids, and host cells for producing said antibodies. Further, the invention relates to the use of said antibodies in the diagnosis and/or treatment of cancers.Type: GrantFiled: November 21, 2017Date of Patent: March 7, 2023Inventors: Christel Iffland, Christina Esdar, Xinyan Zhao, Qi An, Johannes Yeh, Gang Hao, Lars Toleikis, Vanita Sood, David Nannemann, Robin Lytle, Bjoern Hock
-
Publication number: 20230028687Abstract: Compounds of the formula I in which X1, X2, X3, X4, R1, R2, R3, Q and Y have the meanings indicated in claim 1, are inhibitors of c-Kit kinase, and can be employed for the treatment of cancer.Type: ApplicationFiled: October 12, 2021Publication date: January 26, 2023Applicant: MERCK PATENT GMBHInventors: Dieter DORSCH, Mathilde MUZERELLE, Lars BURGDORF, Margarita WUCHERER-PLIETKER, Paul CZODROWSKI, Christina ESDAR, Christos TSAKLAKIDIS
-
Patent number: 11274109Abstract: ?-amino boronic acid derivatives are useful for inhibiting the activity of immunoproteasome (LMP7) and for the treatment and/or prevention of medical conditions affected by immunoproteasome activity such as inflammatory and autoimmune diseases, neurodegenerative diseases, proliferative diseases and cancer.Type: GrantFiled: August 21, 2018Date of Patent: March 15, 2022Assignee: Merck Patent GmbHInventors: Markus Klein, Oliver Schadt, Christina Esdar
-
Patent number: 11186562Abstract: Compounds of the formula I in which X1, X2, X3, X4, R1, R2, R3, Q and Y have the meanings indicated in claim 1, are inhibitors of c-Kit kinase, and can be employed for the treatment of cancer.Type: GrantFiled: February 20, 2020Date of Patent: November 30, 2021Assignee: MERCK PATENT GMBHInventors: Dieter Dorsch, Mathilde Muzerelle, Lars Burgdorf, Margarita Wucherer-Plietker, Paul Czodrowski, Christina Esdar, Christos Tsaklakidis
-
Patent number: 11174241Abstract: Compounds of the formula I in which X1, X2, X3, X4, R1, R2, R3, Q and Y have the meanings indicated in Claim 1, are inhibitors of c-Kit kinase, and can be employed for the treatment of cancer.Type: GrantFiled: February 20, 2020Date of Patent: November 16, 2021Assignee: MERCK PATENT GMBHInventors: Dieter Dorsch, Mathilde Muzerelle, Lars Burgdorf, Margarita Wucherer-Plietker, Paul Czodrowski, Christina Esdar, Christos Tsaklakidis
-
Publication number: 20200354382Abstract: ?-amino boronic acid derivatives are useful for inhibiting the activity of immunoproteasome (LMP7) and for the treatment and/or prevention of medical conditions affected by immunoproteasome activity such as inflammatory and autoimmune diseases, neurodegenerative diseases, proliferative diseases and cancer.Type: ApplicationFiled: August 21, 2018Publication date: November 12, 2020Applicant: Merck Patent GmbHInventors: Markus Klein, Oliver Schadt, Christina Esdar
-
Publication number: 20200190055Abstract: Compounds of the formula I in which X1, X2, X3, X4, R1, R2, R3, Q and Y have the meanings indicated in Claim 1, are inhibitors of c-Kit kinase, and can be employed for the treatment of cancer.Type: ApplicationFiled: February 20, 2020Publication date: June 18, 2020Applicant: MERCK PATENT GMBHInventors: Dieter DORSCH, Mathilde MUZERELLE, Lars BURGDORF, Margarita WUCHERER-PLIETKER, Paul CZODROWSKI, Christina ESDAR, Christos TSAKLAKIDIS
-
Publication number: 20200190054Abstract: Compounds of the formula I in which X1, X2, X3, X4, R1, R2, R3, Q and Y have the meanings indicated in claim 1, are inhibitors of c-Kit kinase, and can be employed for the treatment of cancer.Type: ApplicationFiled: February 20, 2020Publication date: June 18, 2020Applicant: MERCK PATENT GMBHInventors: Dieter DORSCH, Mathilde MUZERELLE, Lars BURGDORF, Margarita WUCHERER-PLIETKER, Paul CZODROWSKI, Christina ESDAR, Christos TSAKLAKIDIS
-
Patent number: 10669251Abstract: Compounds of the formula I in which X1, X2, X3, X4, R1, R2, R3, Q and Y have the meanings indicated in Claim 1, are inhibitors of c-Kit kinase, and can be employed for the treatment of cancer.Type: GrantFiled: December 16, 2016Date of Patent: June 2, 2020Assignee: MERCK PATENT GMBHInventors: Dieter Dorsch, Mathilde Muzerelle, Lars Burgdorf, Margarita Wucherer-Plietker, Paul Czodrowski, Christina Esdar, Christos Tsaklakidis
-
Publication number: 20190367620Abstract: The present invention relates to antibodies with specificity for FGFR1. More particularly, the invention relates to monoclonal antibodies that bind specifically to and neutralize human, macaque and mouse forms of FGFR1 with high affinity. The invention also relates to nucleic acids encoding said antibodies, vectors for expression of these nucleic acids, and host cells for producing said antibodies. Further, the invention relates to the use of said antibodies in the diagnosis and/or treatment of cancers.Type: ApplicationFiled: November 21, 2017Publication date: December 5, 2019Inventors: CHRISTEL IFFLAND, CHRISTINA ESDAR, XINYAN ZHAO, QI AN, JOHANNES YEH, GANG HAO, LARS TOLEIKIS, VANITA SOOD, DAVID NANNEMANN, ROBIN LYTLE, BJOERN HOCK
-
Publication number: 20190023685Abstract: Compounds of the formula I in which X1, X2, X3, X4, R1, R2, R3, Q and Y have the meanings indicated in Claim 1, are inhibitors of c-Kit kinase, and can be employed for the treatment of cancer.Type: ApplicationFiled: December 16, 2016Publication date: January 24, 2019Applicant: MERCK PATENT GMBHInventors: Dieter DORSCH, Mathilde MUZERELLE, Lars BURGDORF, Margarita WUCHERER-PLIETKER, Paul CZODROWSKI, Christina ESDAR, Christos TSAKLAKIDIS
-
Patent number: 9751842Abstract: Compounds of the formula I in which R1, X and n have the meanings indicated in Claim 1, are inhibitors of Tankyrase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation.Type: GrantFiled: May 30, 2014Date of Patent: September 5, 2017Assignee: Marck Patent GmbHInventors: Hans-Peter Buchstaller, Dieter Dorsch, Christina Esdar, Birgitta Leuthner
-
Patent number: 9493444Abstract: The invention provides novel substituted azaheterocyclic compounds according to Formula (I), their manufacture and use for the treatment of hyperproliferative diseases such as cancer, inflammatory or degenerative diseases.Type: GrantFiled: January 10, 2013Date of Patent: November 15, 2016Assignees: Merck Patent GmbH, Cancer Research Technology LimitedInventors: Kai Schiemann, Frank Stieber, Christina Esdar
-
Publication number: 20160318876Abstract: Compounds of the formula I in which R1, X and n have the meanings indicated in Claim 1, are inhibitors of Tankyrase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation.Type: ApplicationFiled: May 30, 2014Publication date: November 3, 2016Applicant: Marck Patent GmbHInventors: Hans-Peter BUCHSTALLER, Dieter DORSCH, Christina ESDAR, Birgitta LEUTHNER
-
Patent number: 9481668Abstract: The compound N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-3-fluorophenyl)-5-ethyl-1 -(pyrimidin-5-yl)-1H-pyrazole-4-carboxamide and pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios, is an inhibitor of RON and can be employed, for the treatment of cancer.Type: GrantFiled: May 7, 2014Date of Patent: November 1, 2016Assignee: Merck Patent GmbHInventors: Oliver Schadt, Christina Esdar, Carsten Schultz-Fademrecht, Jan Eickhoff
-
Patent number: 9339503Abstract: Compounds of the formula I in which U, V and W have the meanings indicated in Claim 1, are inhibitors of Tankyrase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation.Type: GrantFiled: January 14, 2013Date of Patent: May 17, 2016Assignee: MERCK PATENT GMBHInventors: Hans-Peter Buchstaller, Christina Esdar, Birgitta Leuthner
-
Publication number: 20160115154Abstract: The compound N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-3-fluorophenyl)-5-ethyl-1-(pyrimidin-5-yl)-1H-pyrazole-4-carboxamide and pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios, is an inhibitor of RON and can be employed, for the treatment of cancer.Type: ApplicationFiled: May 7, 2014Publication date: April 28, 2016Applicant: Merck Patent GmbHInventors: Oliver SCHADT, Christina ESDAR, Carsten SCHULTZ-FADEMRECHT, Jan EICKHOFF